Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

Inclusion Criteria:

Histologically confirmed, adenocarcinoma of the prostate, clinical stage T1c-T3b, N0, M0.
Patient will have clinically negative nodes as established by imaging (pelvic computed tomography (CT), magnetic resonance imaging (MRI)).
The patient will be clinically M0.
Zubrod status 0-1.
No prior pelvic or prostate radiation or chemotherapy for prostate cancer; induction hormonal therapy beginning ≤ 120 days prior to registration is acceptable.

One of the following combinations of factors:

Clinical stage T1c-T2c, Gleason score 2-6 and prostate-specific antigen (PSA) >10 but ≤ 20 Clinical stage T3a-T3b, Gleason score 2-6 and PSA ≤ 20 Clinical stage T1c-T3b, Gleason score 7-10 and PSA ≤ 20

Patients must sign a study-specific consent form prior to registration.

Exclusion Criteria:

Stage T4 disease.
Lymph node involvement (N1).
Evidence of distant metastases (M1).
Radical surgery for carcinoma of the prostate.
Previous hormonal therapy beginning > 120 days prior to registration.
Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up.
Prior transurethral resection of the prostate (TURP).
Prior invasive malignancy(except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (For example, carcinoma in situ of the oral cavity or bladder are permissible).
Hip prosthesis.